These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38002612)

  • 21. Naldemedine: A Review in Opioid-Induced Constipation.
    Blair HA
    Drugs; 2019 Jul; 79(11):1241-1247. PubMed ID: 31267482
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Naldemedine-induced opioid withdrawal with restlessness as the predominant symptom in a palliative care setting.
    Sato R; Ishida M; Uchida N; Sakimoto T; Yamaguchi T; Ooya Y; Takahashi T; Onishi H
    Palliat Support Care; 2023 Oct; 21(5):957-959. PubMed ID: 37350233
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Phase 2b, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain.
    Webster LR; Yamada T; Arjona Ferreira JC
    Pain Med; 2017 Dec; 18(12):2350-2360. PubMed ID: 28371937
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcomes after intravenous opioids in emergency patients: a prospective cohort analysis.
    O'Connor AB; Zwemer FL; Hays DP; Feng C
    Acad Emerg Med; 2009 Jun; 16(6):477-87. PubMed ID: 19426295
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-World Patient Characteristics and Treatment Patterns of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Cancer: A Multicenter Retrospective Chart Review Study.
    Hiruta E; Fujita Y; Imai H; Masuno T; Yamazaki S; Tanaka H; Kamiya T; Ito M; Takei S; Matsuura M; Nishiba H; Mogi J; Kotake M; Koizuka S; Minato K
    Medicina (Kaunas); 2021 Nov; 57(11):. PubMed ID: 34833451
    [No Abstract]   [Full Text] [Related]  

  • 26. A meta-analysis of naldemedine for the treatment of opioid-induced constipation.
    Song X; Wang D; Qu X; Dong N; Teng S
    Expert Rev Clin Pharmacol; 2019 Feb; 12(2):121-128. PubMed ID: 30652502
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and Safety of Naldemedine Administration for Opioid-Induced Constipation in Cancer Patients with Poor Performance Status.
    Fujita Y; Imai H; Hiruta E; Masuno T; Yamazaki S; Tanaka H; Kamiya T; Sandoh M; Takei S; Arai K; Nishiba H; Mogi J; Koizuka S; Saito T; Obayashi K; Kaira K; Minato K
    J Palliat Med; 2023 Apr; 26(4):548-553. PubMed ID: 36971576
    [No Abstract]   [Full Text] [Related]  

  • 28. Onset of action of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: results from 2 randomized, placebo-controlled, phase 3 trials.
    Wild J; Yamada T; Arjona Ferreira JC; Hale M
    Pain; 2019 Oct; 160(10):2358-2364. PubMed ID: 31145214
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy: A Subgroup Analysis of Patients ≥ 65 Years of Age.
    Wild J; Webster L; Yamada T; Hale M
    Drugs Aging; 2020 Apr; 37(4):271-279. PubMed ID: 32086791
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Opioid withdrawal syndrome developing after long-term administration of naldemedine.
    Ishida M; Uchida N; Yabuno A; Hasegawa K; Mizunuma N; Takahashi T; Onishi H
    Palliat Support Care; 2022 Dec; 20(6):897-899. PubMed ID: 35543119
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients With Cancer.
    Katakami N; Oda K; Tauchi K; Nakata K; Shinozaki K; Yokota T; Suzuki Y; Narabayashi M; Boku N
    J Clin Oncol; 2017 Jun; 35(17):1921-1928. PubMed ID: 28445097
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Naldemedine: Peripherally Acting Opioid Receptor Antagonist for Treating Opioid-induced Adverse Effects.
    Inagaki M; Kanemasa T; Yokota T
    Curr Top Med Chem; 2020; 20(31):2830-2842. PubMed ID: 32648846
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors associated with non-response to naldemedine for opioid-induced constipation in cancer patients: A subgroup analysis.
    Kanbayashi Y; Shimizu M; Ishizuka Y; Sawa S; Yabe K; Uchida M
    PLoS One; 2022; 17(12):e0278823. PubMed ID: 36490241
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-World Evidence for the Safety and Effectiveness of Naldemedine in the Management of Opioid-Induced Constipation in Patients With Cancer Pain: Post-hoc Subgroup Analysis of Post-marketing Surveillance in Japan.
    Naya N; Oka H; Hashimoto S; Morioka Y; Kizawa Y
    Cureus; 2023 Sep; 15(9):e46090. PubMed ID: 37900431
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of paravertebral blocks on analgesic and non-analgesic outcomes after video-assisted thoracoscopic surgery: A propensity matched cohort study.
    Ranganath YS; Ramanujam V; Onodera Y; Keech J; Arshava E; Parekh KR; Sondekoppam RV
    PLoS One; 2021; 16(5):e0252059. PubMed ID: 34015047
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Naldemedine in Japanese patients with opioid-induced constipation and chronic noncancer pain: open-label Phase III studies.
    Saito Y; Yokota T; Arai M; Tada Y; Sumitani M
    J Pain Res; 2019; 12():127-138. PubMed ID: 30613161
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Naldemedine Improves Patient-Reported Outcomes of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain in the COMPOSE Phase 3 Studies.
    Camilleri M; Hale M; Morlion B; Tack J; Webster L; Wild J
    J Pain Res; 2021; 14():2179-2189. PubMed ID: 34295186
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Drug-Drug Interaction Studies to Evaluate the Effects of a P-Glycoprotein Inhibitor, CYP3A Inhibitors, and a CYP3A Inducer on the Pharmacokinetics of Naldemedine in Healthy Subjects.
    Fukumura K; Kawaguchi N; Ishibashi T; Kubota R; Tada Y; Ogura E
    Clin Drug Investig; 2020 Jun; 40(6):529-540. PubMed ID: 32323104
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparing the effectiveness of magnesium oxide and naldemedine in preventing opioid-induced constipation: a proof of concept, single institutional, two arm, open-label, phase II, randomized controlled trial: the MAGNET study.
    Ozaki A; Kessoku T; Iwaki M; Kobayashi T; Yoshihara T; Kato T; Honda Y; Ogawa Y; Imajo K; Higurashi T; Yoneda M; Taguri M; Yamanaka T; Ishiki H; Kobayashi N; Saito S; Ichikawa Y; Nakajima A
    Trials; 2020 Jun; 21(1):453. PubMed ID: 32487150
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.